Hal Martin

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E. Sax, David A. Wohl, Michael T. Yin et al. · The Lancet · 2015 · 598 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Joel E. Gallant, Adriano Lazzarin, Anthony Mills et al. · The Lancet · 2017 · 380 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy

Paul E. Sax, Andrew Zolopa, Indira Brar et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2014 · 206 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Jean‐Michel Molina, Douglas Ward, Indira Brar et al. · The Lancet HIV · 2018 · 203 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Eric S. Daar, Edwin DeJesus, Peter Ruane et al. · The Lancet HIV · 2018 · 180 citations

Medicine, Infectious Diseases, Pharmacology +16